New Data in Nature Medicine Suggest Pre-Treatment Tumor Microenvironment Can Impact Response for CAR T-Cell Therapy in Patients with Large B-Cell Lymphoma

Author's Avatar
Aug 29, 2022

Veracyte%2C+Inc. (Nasdaq: VCYT) announced that new data published today in Nature+Medicineprovide the first evidence that the pre-treatment tumor microenvironment (TME) can impact response to chimeric-antigen-receptor (CAR) T-cell therapy among patients with large B-cell lymphoma (LBCL). The study findings demonstrated for the first time the prognostic and predictive capabilities of Veracyte’s proprietary biomarkers among LBCL patients treated with CAR T-cell therapy.